CAS: 2131803-90-0

WYC-209

WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs, IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).

WYC-209 is a synthetic compound that has the potential to be an effective cancer therapy. It inhibits the activity of signal pathways that are involved in tumor development, including the PI3K/Akt and ERK1/2 pathways. The molecule also inhibits the expression of IL-6 and IL-8, which are cytokines that stimulate tumor growth. This drug may also inhibit cancer stem cells, which are responsible for tumor recurrence. WYC-209 has not been tested on humans, but studies have shown it to be safe in mice with melanoma. It has been shown to inhibit the growth of tumors in these animals without any toxicity or side effects.